FEATURED NEWS
Delve founder, Dr. Michael Wilson, MD has been selected as the recipient of the 2023 ANA Awards for Excellence
This award was established to recognize an individual who has made novel scientific contributions that reshape the field’s conceptual understanding of specific neurological syndromes or diseases, novel or sustained contributions through the development of new therapeutics for neurological diseases, and/or a major contribution that transforms or expands diagnostic tools in neurology.
Delve Neuro
Delve Neuro provides pathogen-agnostic and unbiased detection of neuro-infectious pathogens in cerebrospinal fluid (CSF) in one shot.
- Samples the entire metagenomic content – DNA and RNA – within a patient sample.
- Uses a proprietary mNGS bioinformatic pipeline to rapidly analyze millions of sequences.
- Rapidly and accurately identifies bacterial, viral, fungal, and parasitic species.
As exclusive licensee of University of California San Francisco’s (UCSF) metagenomic sequencing (mNGS) technology, Delve Bio leverages mNGS to empower labs and clinicians with the results they need to diagnose routine and rare infectious diseases.
Meet the Delve Team
Leadership
Founders
Michael Wilson, MD
Professor, University of California San Francisco
https://wilsonlab.ucsf.edu
Pardis Sabeti, MD, PhD
Professor, Harvard University
Institute Member, Broad Institute
https://www.sabetilab.org

Joe DeRisi, PhD
Professor, University of California San Francisco
President, Chan Zuckerberg Biohub
https://derisilab.ucsf.edu
Matthew Meyerson, MD, PhD
Director, Center for Cancer Genomics, Dana-Farber Cancer Institute
Professor of Genetics and Medicine, Harvard Medical School
Institute Member, Cancer Program, Broad Institute
https://meyersonlab.dana-farber.org
Charles Chiu, MD, PhD
Professor, Laboratory Medicine and Medicine / Infectious Diseases, University of California, San Francisco
Associate Director, UCSF Clinical Microbiology Laboratory
Investigator, Chan-Zuckerberg Biohub
https://chiulab.ucsf.edu